Novo Nordisk faces new GLP-1 rival as Eli Lilly's triple agonist sets weight-loss record

Citi said Eli Lilly and Co's (NYSE:LLY) experimental obesity drug retatrutide has set a new competitive benchmark for the GLP-1 weight-loss market after a pivotal trial showed patients losing 28% of their body weight over 80 weeks at the highest dose. The results from the TRIUMPH-1 trial, the first dedicated phase III obesity study of the triple agonist drug, were broadly in line with the previously reported TRIUMPH-4 trial in obesity and knee osteoarthritis patients, which showed 28.7% weight loss at 68 weeks.